Citi Downgrades Human Genome Sciences (HGSI) to Hold, Cuts Target
Tweet Send to a Friend
Get Alerts HGSI Hot Sheet
Price: $14.24 --0%
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade HGSI Now!
Citi downgraded Human Genome Sciences (NASDAQ: HGSI) from Buy to Hold and cut their price target from $35 to $30. The downgrade comes despite FDA panel backing of Benlysta yesterday afternoon.
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $25.88 yesterday, with a 52 week range of $20.56-$34.49.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $25.88 yesterday, with a 52 week range of $20.56-$34.49.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Macquarie Downgrades Barrick Gold (ABX) to Underperform
- Deutsche Bank Downgrades TRW Automotive Holdings (TRW) to Hold
- Baird Downgrades Brocade (BRCD) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Citi
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
